Wegovy Tablets Vs Injection

If you have been struggling with your weight for years and feel like you have tried everything — calorie counting, exercise plans, meal replacements — you will understand exactly how demoralising it can be when nothing seems to work long-term. The good news is that 2026 has brought renewed hope, and Wegovy tablets are at the centre of that conversation. This clinically proven weight loss treatment, based on the active ingredient semaglutide, is now one of the most talked-about medicines in the UK, and for good reason.

Quick Summary

Wegovy is an MHRA-approved injectable treatment containing semaglutide that mimics the GLP-1 hormone to reduce hunger and support significant, sustained weight loss. It is suitable for adults with a BMI of 30 or above, or 27 and above with a weight-related health condition.

• Wegovy contains semaglutide, a GLP-1 receptor agonist that suppresses appetite at the brain level
• Clinical trials show average weight loss of around 15% of body weight over 68 weeks
• Treatment begins at 0.25 mg weekly and increases gradually to 2.4 mg
• Common side effects include nausea, vomiting, and constipation — most improve with time
• Available in the UK through private prescription from registered prescribers, including online services

Table of Contents

• What Is Wegovy and How Does Semaglutide Work?
• Who Is Eligible for Wegovy in the UK?
• Wegovy Dosing Schedule Explained Step by Step
• Managing Side Effects: What to Expect and When to Worry
• Wegovy Compared to Other Weight Loss Treatments in the UK
• How to Get Wegovy Safely Through a UK Prescriber
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• Frequently Asked Questions

What Is Wegovy and How Does Semaglutide Work?

If you have heard the term GLP-1 receptor agonist thrown around lately but are not entirely sure what it means in plain English, you are not alone. Wegovy tablets — more precisely, the Wegovy injectable pen containing semaglutide — belongs to a class of medicines that mimic a hormone your body already produces naturally called glucagon-like peptide-1, or GLP-1. This hormone is released from the gut after eating and plays a central role in telling your brain that you are full.

When semaglutide binds to GLP-1 receptors in the brain, it amplifies these fullness signals significantly. The result is that you naturally eat less, feel satisfied sooner, and experience fewer intense food cravings throughout the day. Unlike older diet pills that relied on stimulants or fat blockers, this mechanism works with your body's own biology rather than against it. That is a fundamental reason why clinical results have been so much more impressive than previous generations of weight loss medicines.

It is worth clarifying a common misconception here. Many people search for Wegovy tablets expecting a pill, but Wegovy is currently administered as a subcutaneous injection using a pre-filled pen device. The injection is self-administered once weekly, typically into the abdomen, thigh, or upper arm. The pen is straightforward to use, and most people find they become comfortable with the process within their first few doses. You can explore more about weight management options through our general health treatments section.

• Semaglutide mimics the GLP-1 hormone that signals fullness to your brain
• Wegovy is a once-weekly subcutaneous injection, not an oral tablet
• It reduces both appetite and the reward-driven urge to overeat
• The mechanism is fundamentally different from older stimulant-based diet pills
• MHRA-approved and supported by robust clinical evidence from large-scale trials

Who Is Eligible for Wegovy in the UK?

Not everyone who wants to lose weight will qualify for Wegovy, and understanding the eligibility criteria upfront can save you time and frustration. In the UK, Wegovy is approved for adults who meet specific BMI thresholds. To qualify, you need a BMI of 30 kg/m² or above (classified as obese), or a BMI of at least 27 kg/m² alongside at least one weight-related health condition. These conditions include type 2 diabetes, high blood pressure, sleep apnoea, dyslipidaemia, or cardiovascular disease.

Wegovy tablets are intended to complement, not replace, lifestyle changes. Prescribers will typically require you to also commit to a calorie-reduced diet and increased physical activity. This is not a bureaucratic hurdle — it is because the treatment is significantly more effective when combined with lifestyle modification. The clinical trials that achieved that headline-grabbing 15% average body weight reduction were all conducted alongside such programmes.

There are also contraindications to be aware of. Wegovy is not suitable for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not recommended during pregnancy or breastfeeding. People with a history of pancreatitis should discuss the risk carefully with their prescriber before starting treatment. Your prescriber will conduct a thorough assessment to ensure Wegovy is appropriate and safe for your individual health profile.

• BMI of 30 or above, or 27 and above with a weight-related health condition
• Must commit to dietary and lifestyle changes alongside treatment
• Not suitable during pregnancy, breastfeeding, or with a history of thyroid cancer
• People with pancreatitis history require careful clinical review first
• A full medical history assessment is required before prescribing

Wegovy Dosing Schedule Explained Step by Step

One of the most common concerns people have when starting a new injectable treatment is whether the dosing will be complicated or difficult to manage. The good news is that Wegovy's dosing schedule is straightforward, predictable, and designed with patient comfort firmly in mind. The gradual dose escalation approach is one of the key reasons why the majority of patients are able to tolerate the treatment well and stay on course for the full recommended duration.

Treatment begins at 0.25 mg once per week for the first four weeks. This starting dose is not intended to produce significant weight loss — its purpose is to allow your body to adjust to semaglutide gradually. After four weeks, the dose increases to 0.5 mg weekly, then 1.0 mg, then 1.7 mg, and finally reaches the maintenance dose of 2.4 mg weekly. Each step up occurs at four-week intervals, meaning the full escalation takes approximately 16 to 20 weeks to complete. Wegovy tablets (semaglutide) then continue at 2.4 mg indefinitely for as long as treatment is clinically appropriate.

It is important to inject on the same day each week to maintain consistent semaglutide levels in your system. If you miss a dose and the next scheduled injection is more than two days away, you can take the missed dose. If it is less than two days away, skip it and continue with your normal schedule. Never double up on doses. Our team of UK-based pharmacists is always available to provide guidance on your treatment through our general health support services.

• Start at 0.25 mg weekly for the first four weeks
• Increase every four weeks: 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg
• Full maintenance dose of 2.4 mg is typically reached around week 17
• Inject on the same day each week for consistency
• Store Wegovy pens in the fridge between 2–8°C until ready to use

Week	Dose	Primary Purpose	Expected Effect
Weeks 1–4	0.25 mg weekly	Initiation / body adjustment	Minimal weight loss; gut adaptation
Weeks 5–8	0.5 mg weekly	Dose escalation	Appetite begins to reduce noticeably
Weeks 9–12	1.0 mg weekly	Continued escalation	Early measurable weight loss
Weeks 13–16	1.7 mg weekly	Near-maintenance escalation	Significant reduction in hunger and cravings
Week 17 onwards	2.4 mg weekly	Maintenance dose	Sustained weight loss; peak efficacy
Week 68 (trial end)	2.4 mg weekly	Long-term continuation	Average 15% body weight reduction in trials

Managing Side Effects: What to Expect and When to Worry

No medicine is without its side effects, and Wegovy is no exception. However, understanding what is common, what is manageable, and what is genuinely concerning makes a significant difference to how people experience the treatment. The vast majority of side effects associated with Wegovy are gastrointestinal in nature, and most are mild to moderate and temporary — particularly during the dose escalation phase.

The most frequently reported side effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are most pronounced when moving from one dose level to the next and typically settle within a few days to a couple of weeks. Eating smaller meals, avoiding fatty or spicy foods, and staying well hydrated can help considerably. If nausea is particularly troublesome, eating bland foods such as crackers or dry toast before and after your injection may help. Wegovy tablets — semaglutide in its injectable form — work best when supported by mindful eating habits from day one.

More serious but less common side effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, and in rare cases, increased heart rate. There have also been reports of a condition sometimes called "Ozempic face" — where rapid weight loss leads to facial volume changes — though this is cosmetic rather than medically dangerous. If you experience severe or persistent abdominal pain, jaundice, or vision changes, seek medical attention promptly. Always keep your prescriber informed of any new symptoms throughout treatment.

• Nausea, vomiting, and constipation are the most common side effects
• Most GI symptoms peak during dose escalation and then ease considerably
• Eating smaller, blander meals can reduce the severity of nausea
• Seek urgent advice for severe abdominal pain, jaundice, or fast heartbeat
• Regular check-ins with your prescriber help catch any concerns early

Wegovy Compared to Other Weight Loss Treatments in the UK

The UK weight loss medication landscape has changed dramatically over the past few years. Alongside Wegovy, patients may also hear about Ozempic (the diabetes formulation of semaglutide at a lower dose), Mounjaro (tirzepatide), and Saxenda (liraglutide). Each has its place, but understanding how they differ helps you and your prescriber make the best decision for your individual situation.

Wegovy contains semaglutide at a dose specifically optimised for weight management, reaching 2.4 mg weekly. Ozempic, while containing the same active ingredient, is licensed for type 2 diabetes management and reaches a maximum dose of 1.0 mg or 2.0 mg weekly — not approved for weight loss. Saxenda (liraglutide) is an older GLP-1 receptor agonist requiring daily injection, with slightly less impressive average weight loss outcomes compared to Wegovy. Mounjaro, a dual GIP/GLP-1 receptor agonist, has shown even greater average weight loss in some trials and is now a key competitor in 2026. The right choice depends on your medical history, tolerability, preferences, and cost considerations.

Cost is a practical reality many people face. Wegovy through the NHS remains limited in availability due to supply and commissioning constraints, meaning many patients access it through private prescription services. Private online pharmacies registered with the Care Quality Commission (CQC) and employing GPhC-registered prescribers offer a legitimate, safe, and often more accessible route to Wegovy than waiting for NHS pathways to open up in your area.

• Wegovy (semaglutide 2.4 mg) is specifically licensed for weight management in the UK
• Ozempic uses the same ingredient but at a lower dose for diabetes only
• Saxenda requires daily injections and shows slightly lower average weight loss
• Mounjaro (tirzepatide) is a strong alternative showing excellent results in 2026 trials
• Private prescription services offer a legitimate and accessible route to treatment

How to Get Wegovy Safely Through a UK Prescriber

One of the biggest pain points for people who want to try Wegovy is navigating how to actually access it. With NHS availability still restricted in many areas of England, Scotland, Wales, and Northern Ireland, many people find themselves on long waiting lists or unable to access treatment through their GP at all. This is where regulated private services, including online pharmacy consultations with qualified prescribers, fill a critical gap.

The key to accessing Wegovy safely is ensuring you use a service that is fully regulated. In the UK, any business supplying prescription-only medicines online must be registered with the Care Quality Commission (CQC) if it is providing clinical services, and any pharmacist or prescriber must be registered with the General Pharmaceutical Council (GPhC) or the General Medical Council (GMC). Always look for GPhC registration numbers displayed clearly, and check they are valid on the GPhC register before purchasing. Cured Pharmacy employs prescribing pharmacists including GPhC-registered professionals who conduct thorough online assessments to ensure Wegovy is appropriate for you before any prescription is issued.

Once approved, Wegovy is typically dispatched in discreet, temperature-controlled packaging to protect the integrity of the medication. You should receive clear instructions on how to administer the injection, how to dispose of the pen safely, and what to do if you experience any concerns. Ongoing support and monitoring are an essential part of responsible prescribing, and reputable services will schedule follow-up consultations to track your progress and adjust your treatment plan if needed. You can access our health and wellness support services to start your journey with confidence.

• Choose a CQC-registered online service with GPhC-registered prescribers
• A full medical assessment must be completed before a prescription is issued
• Wegovy is delivered in temperature-controlled, discreet packaging
• Follow-up monitoring is essential — look for services that provide ongoing support
• Never buy injectable weight loss treatments from unregulated sources or social media sellers

Key Takeaways

• Wegovy (semaglutide 2.4 mg) is an MHRA-approved once-weekly injection for weight management, available in the UK to eligible adults
• Clinical trials demonstrate an average body weight reduction of approximately 15% over 68 weeks when combined with lifestyle changes
• The dose escalation schedule starting at 0.25 mg helps minimise GI side effects and improves long-term tolerability
• Always access Wegovy through a registered UK prescriber — never from unregulated online sellers or unlicensed sources
• In 2026, private prescription services offer the most accessible and timely route to treatment for most UK adults who qualify

When to Seek Professional Advice

While Wegovy is a well-tolerated treatment for the majority of users, there are specific circumstances where you should contact your prescriber or seek urgent medical attention without delay. Being informed about these warning signs means you can act quickly and protect your health throughout your weight loss journey.

Contact your prescriber or GP promptly if you experience any of the following:

• Severe, persistent abdominal pain — particularly pain that radiates to your back — which could indicate pancreatitis
• Yellowing of the skin or whites of the eyes (jaundice), which may suggest gallbladder or liver issues
• A noticeable and sustained increase in resting heart rate
• Symptoms of low blood sugar (if you are also taking diabetes medication), including shakiness, sweating, and confusion
• Signs of a severe allergic reaction such as facial swelling, difficulty breathing, or widespread rash
• Significant mood changes or new or worsening feelings of depression or suicidal thoughts
• Any new or unusual symptoms that concern you — when in doubt, always reach out

You should also consult your prescriber before stopping Wegovy suddenly, as weight can return without a managed tapering plan or transition strategy. Your prescriber can work with you to plan a responsible exit from treatment if that becomes necessary.

Scientific References

1. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology Appraisal Guidance TA875. NICE, 2023.
2. Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory approval of Wegovy (semaglutide). MHRA, 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021; 384:989–1002. (STEP 1 Trial — cited in UK NICE review)

Frequently Asked Questions

How long does it take for Wegovy to start working?

Wegovy tablets (semaglutide injection) typically begin reducing appetite within the first one to two weeks, though meaningful weight loss is usually noticeable after four to eight weeks. Most clinical trials show the greatest results after 68 weeks of consistent use alongside a reduced-calorie diet and regular physical activity.

Is Wegovy safe to use long-term in the UK?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified UK prescriber. The MHRA-approved treatment has been evaluated in large-scale trials lasting over a year, and in 2026 it continues to be recommended within NICE guidelines for eligible adults managing obesity with related health conditions.

Can you take Wegovy with other medications?

Wegovy can interact with certain medicines, particularly oral medications that depend on absorption timing, such as some diabetes drugs and thyroid treatments. You should always disclose your full medication list to your prescriber before starting Wegovy, as adjustments may be needed to ensure both safety and treatment effectiveness.

What is the starting dose of Wegovy semaglutide?

The starting dose of Wegovy semaglutide is 0.25 mg once weekly, which is gradually increased every four weeks up to the maintenance dose of 2.4 mg weekly. This slow dose escalation is intentional and helps minimise gastrointestinal side effects, making the treatment more comfortable and sustainable over the treatment period.